In this GEN webinar, Mark Perreault will discuss strategies for improving mAb manufacturing using the latest technologies for separating, purifying, and concentrating therapeutic biomolecules.

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.

USP's well-characterized mAb and AAV standards, when paired with Bio-Techne's MauriceFlex system, enable efficient analysis of purity, size, charge, and identity in complex biologics.

Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno ...

Bio-Techne Corp. TECH has recently entered into a distribution agreement with the U.S. Pharmacopeia (“USP”) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference ...

This leads to a greater need for manufacturers to rigorously test critical quality attributes throughout mAb development and manufacturing processes to demonstrate product safety and effectiveness.

This leads to a greater need for manufacturers to rigorously test critical quality attributes throughout mAb development and manufacturing processes to demonstrate product safety and effectiveness.

I-Mab’s financial position remains strong, with cash and equivalents of approximately $168.6 million, expected to support operations into 2027.

The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development.